Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Date:12/9/2008

with multiple myeloma. We believe this data supports moving Perifosine into a phase 3 program and we are currently exploring the design of a randomized phase 3 placebo controlled clinical trial."

Two additional clinical posters were presented as follows:

Abstract 3691: Phase 1 Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

Thirty of 32 patients enrolled were evaluable for response. Perifosine in combination with Revlimid(R) + dexamethasone achieved a 70% ORR (MR or greater), with 50% of patients achieving at least a partial response (PR). The median progression-free survival (PFS) for the 21 patients (70%) who achieved at least an MR is 10.9 months as of November 2008 (not reached). Twenty-three of the 30 evaluable patients are still alive and the median overall survival has not been reached at 16.8 months. Ten patients remain on active treatment.

Abstract 1010: Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom's Macroglobulinemia (WM)

Single agent perifosine achieved a 36% ORR (MR, PR) and 58% stable disease in a heavily pre-treated Waldenstrom's Macroglobulinemia patient population. Clinical benefit was demonstrated as reflected by a median time to progression of 10.7 months.

KRX-0401 (Perifosine) Mechanism of Action and Profile

KRX-0401 (Perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in th
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
6. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
10. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
11. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
(Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
(Date:7/24/2014)... night, which shuts off nighttime production of the hormone ... widely used breast cancer drug, says a new study ... study, "Circadian and Melatonin Disruption by Exposure to Light ... Breast Cancer," published in the journal Cancer Research ... vital to the success of tamoxifen in treating breast ...
(Date:7/24/2014)... Ticket Down is a reliable source for cheap ... Sports Authority Field on July 26th. For the past four years, ... of the best club teams from around the world to North ... about weeks after its completion, fans – new and old alike ... stars in the world compete. Some of these players were already ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Four ... this month of its $3 million renovation of the ... Lokelani presidential/residential three-bedroom suites, just in time to welcome ... , With design direction from the internationally-acclaimed BraytonHughes Design ... largest on the property and the largest in Hawaii—received ...
(Date:7/24/2014)... In a July 9th article in the ... Lotus Blossom Consulting LLC , was quoted in a ... to Cut the High Cost of Infertility . Her advice ... to maximize your chance of success from the first attempt.” ... , “I am always happy to talk with the ...
(Date:7/24/2014)... County, NJ (PRWEB) July 24, 2014 ... a leading specialist in hematology and oncology, Dr. ... Medical Group. Our system welcomes Dr. Upadhyaya to ... physicians comprise CarePoint Health Medical Group, a comprehensive ... County, representing a wide range of specialties. This ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2
... claimed five more victims in Bataan, Rizal and Marikina ... from Valenzuela City and a four-and-a-half child from Balanga, ... administrator of the Amang Rodriguez Medical Center the Valenzuela ... hours after being taken there for treatment Wednesday. ...
... to combat tropical diseases that ails many millions of ... was given a renewed thrust by The Bill & ... more than $68.2 million. ,This fund will ... trypanosomiasis – which are spread by parasites and worms. ...
... Rooney, Coleen McLoughlin launched Children’s Hospice Week in the ... of the work hospices do as well as aid ... has personal experience to speak from. Her eight-year-old sister, ... a regular visitor to Claire House Children’s Hospice in ...
... review that was published in the Friday’s issue of the British ... of fractures in the later years.// ,According to the ... age of 18 years. Hence, it is expected that enhancing bone ... bone loss and osteoporosis. ,The results of 19 studies, ...
... technique to find out if metastasis from the eye cancer ... scientists at Washington University School of Medicine in St. Louis ... of the eye might spread to the liver, where it ... also of the opinion that the molecular screening test might ...
... postmenopausal women with any risk levels of breast cancer. According ... September 1 issue of Clinical Cancer Research//, Raloxifene could protect ... they are at high or low risk of developing the ... drug could reduce the risk in women with a family ...
Cached Medicine News:Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 2Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 3Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 4Health News:Raloxifene Reduces The Risk Of Breast Cancer 2Health News:Raloxifene Reduces The Risk Of Breast Cancer 3
... Tests are qualitative enzyme immunoassays (EIA) for ... (IgG or IgM, respectively) in serum. Equivocal ... be supplemented with a standardized western blot ... to support a clinical diagnosis of B. ...
... Thyroid Autoimmunity Test is an enzyme immunoassay ... autoantibodies against human thyroglobulin and human thyroid ... blood and is used as an aid ... thyroid gland disorders are characterized by detection ...
... is dot-blot assay system combining microwell EIA ... purified antigen set at a clinically meaningful ... is detected using the same reagent system ... combines antigens detected in Auto 4 detecting ...
... The ImmunoDOT Autoimmunity Screening Panel 4 ... for screening and detection of autoantibodies ... (SS-A, SS-B, RNP/Sm, and Sm) in ... aid in the diagnosis of systemic ...
Medicine Products: